RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Conditional marketing approval (China), Orphan Drug (Japan), Special Review Project (China), Fast Track (United States)

Structure/Sequence

Molecular FormulaC40H57N5O7

InChIKeyBLMPQMFVWMYDKT-NZTKNTHTSA-N

CAS Registry868540-17-4

Sequence Code 16182110

263

Clinical Trials associated with Carfilzomib

NCT07479979

/ Not yet recruitingPhase 1/2IIT

Phase Ib/II Study of Selinexor in Combination With Carfilzomib, Subcutaneous Isatuximab Administered Via Investigational Device and Dexamethasone (SCID) for Patients With Relapsed and/or Relapsed Refractory Multiple Myeloma

The primary objective of this Phase Ib/II trial is to study the safety and tolerability of the combination of selinexor, carfilzomib, isatuximab-OBDS** and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma, who have received at least one line of therapy. The phase Ib portion comprises the safety run-in with 6-12 patients, with the option to reduce the selinexor dose from 40 mg to 20 mg if the higher dose reaches the prescribed toxicity threshold. The Phase II portion of the trial will test the RP2D in an expansion cohort of up to 50 patients.

Start Date01 Jul 2026

Sponsor / Collaborator

Hoosier Cancer Research Network

[+3]

NCT06918990

/ Not yet recruitingPhase 2IIT

Targeting the B Cell Response to Treat Antibody-Mediated Rejection With Carfilzomib and Belatacept (CarBel)

The purpose of this study is to see:
1. If using these two drugs (carfilzomib and belatacept) together is safe
2. If the use of these two study drugs in addition to the usual immunosuppression for kidney transplant patients can improve your transplanted kidney function by lowering the antibodies you have against your transplanted kidney
3. If the study drugs effect the immune cells that were responding to your donor kidney. And, whether blood or urine tests can measure signs of inflammation and kidney cell injury
4. If using new computer techniques can help describe important changes seen on biopsy in your donated kidneys
The primary objective is to assess the efficacy of carfilzomib and belatacept therapy when added to current treatment with steroids and maintenance immunosuppression, compared to conventional treatment alone, to improve the clinical outcome in renal transplant patients with donor-specific antibody (DSA) and associated graft injury occurring more than 6 months after renal transplantation or less than 6 months post-transplant.

Start Date15 Apr 2026

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

NCT07082270

/ Not yet recruitingPhase 1IIT

Phase I Trial of GB1211 (Selvigaltin), an Oral Galectin-3 (Gal-3) Inhibitor, Combined With Standard of Care Treatment in Relapsed/Refractory Multiple Myeloma (RRMM)

This phase I trial studies the side effects and best dose of selvigaltin when given together with standard of care treatment (daratumumab-hyaluronidase, carfilzomib, dexamethasone) in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Selvigaltin works by blocking the activity of a protein called galectin-3. Galectin-3 is involved in various cellular processes, including inflammation and tissue scarring, which is associated with worse outcomes in several forms of cancer. By blocking the activity of galectin-3, selvigaltin may help reduce inflammation and tissue scarring. Daratumumab-hyaluronidase is a drug composed of daratumumab and hyaluronidase. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Hyaluronidase helps deliver the daratumumab to CD38-expressing cancer cells. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving selvigaltin with standard of care treatment may be safe, tolerable, and/or effective in treating patients with relapsed or refractory multiple myeloma.

Start Date01 Apr 2026

Sponsor / Collaborator

Roswell Park Comprehensive Cancer Center

100 Clinical Results associated with Carfilzomib

100 Translational Medicine associated with Carfilzomib

100 Patents (Medical) associated with Carfilzomib

2,222

Literatures (Medical) associated with Carfilzomib

01 Dec 2026·JOURNAL OF MOLECULAR MEDICINE-JMM

Anti-myeloma activity of the CXCR4 antagonist WZ811

Article

Author: Suroviakova, Katarina ; Sedlak, Jan ; Jakubikova, Jana ; Valuskova, Zuzana ; Strizova, Anna ; Marinkovicova, Maria Elisabeth ; Csicsatkova, Nikoleta ; Cholujova, Danka

Abstract:

The CXCR4-CXCL12 axis is crucial for the interaction between malignant plasma cells (PC) and their microenvironment in multiple myeloma (MM). Here, we show that CXCR4 expression is upregulated in MM cell lines and PCs during both premalignant and active stages of MM, compared to normal PCs from healthy donors. The CXCR4 antagonist WZ811 reduced the viability of MM PCs and cell lines, while tumor microenvironment cells from both MM patients and healthy donors exhibited significant resistance. In vivo, WZ811 significantly reduced tumor burden and improved survival. WZ811-mediated MM cell death involved disruption of mitochondrial transmembrane potential, externalization of transmembrane phosphatidylserine, activation of caspases, increased levels of autophagic proteins, and an increase in G 0 /G 1 phase of the cell cycle. WZ811 also eliminated the MM stem cell-like side population, though slight resistance was observed with stromal cells. Additionally, WZ811 increased levels of CXCL12 and extracellular matrix molecules collagen IV and laminin in MM cells. Combining WZ811 with anti-MM agents showed synergism with doxorubicin, dexamethasone, bortezomib, lenalidomide, and pomalidomide, while antagonism was observed with carfilzomib, supporting the clinical assessment of WZ811 in MM.

Key messages:

WZ811 reduced the viability of myeloma primary cells and cell lines.WZ811 reduced tumor burden and improved survival in vivo xenograft model.WZ811 mechanisms involved apoptotic and autophagic cell death.WZ811 eliminated the MM stem cell-like side population.WZ811 synergized with DOX, DEX, BTZ, LEN, and POM.

01 Jun 2026·COLLOIDS AND SURFACES B-BIOINTERFACES

A quality by design study of the use of microfluidic nanoprecipitation for the generation of sub-100 nm drug nanocrystals

Article

Author: Abukhamees, Shorooq ; Craig, Duncan Q M ; Ozsoy, Yildiz ; Demiralp, Burcu ; Fitaihi, Rawan ; Pirincci Tok, Yagmur

Although drug nanocrystals have attracted considerable interest within the pharmaceutical industry, there remain issues with the production of nanocrystals with a size below 100 nm. The aim of the present study is to develop a stable, reproducible Canagliflozin (CFZ) sub-100 nm nanosuspension system using microfluidic nanoprecipitation and Quality by Design (QbD) techniques. By means of the circumscribed central composite design (CCCD), critical parameters of the microfluidic nanoprecipitation process and nanosuspension formulation components were optimised. Optimal CFZ nanosuspension with Z-average of 89.52 ± 3.30 nm, PDI of 0.12 ± 0.01 and drug content of 92.49 ± 0.03 % was successfully fabricated using Soluplus as a stabiliser. An increase in saturation solubility corresponding to approximately 250 times the value of the pure CFZ in water was noted. The optimised CFZ nanosuspension was solidified by freeze-drying and electrospraying. Overall, the study has demonstrated that by using a combination of microfluidics and QbD it is promising to generate stable sub-100 nm nanocrystals with high yield, and narrow size distribution and favourable stability.

02 Mar 2026·MOLECULAR PHARMACEUTICS

Liposome-Encapsulated Carfilzomib as a Radiosensitizer in Solid Tumors

Article

Author: Skrodzki, David ; Saha, Pranay ; Pan, Dipanjan ; Machtay, Mitchell ; Molinaro, Matthew

Chemoradiotherapy is a common treatment option for many cancers. Carfilzomib (CFZ) is an effective chemotherapeutic drug with a multitude of cellular effects. However, CFZ has yet to be studied in the context of chemoradiotherapy. To study the application of CFZ in chemoradiotherapy, we synthesized CFZ-loaded liposomes. We report a novel liposomal formulation of the proteasome inhibitor CFZ designed to enhance tumor radiosensitivity while improving drug solubility and tolerability. CFZ-loaded PEGylated liposomes were synthesized via thin-film hydration and probe sonication, achieving an average diameter of ∼127 nm and an encapsulation efficiency of 64%. In murine 4T1 breast carcinoma cells, CFZ treatment prior to irradiation significantly reduced clonogenic survival (dose enhancement factor = 1.26) and increased γ-H2AX foci retention, indicating impaired DNA double-strand break repair. In a dual-flank Balb/cJ allograft model, local intratumoral administration of CFZ followed by ionizing radiation (8 Gy × 2) markedly suppressed primary tumor growth compared with monotherapies without inducing systemic toxicity. Although a strong abscopal effect on distant tumors was not observed, the combination treatment reduced the pulmonary metastatic burden relative to controls. Collectively, these results demonstrate that liposomal carfilzomib can act as an effective radiosensitizer, functioning through perturbation of DNA repair and modulation of the tumor response to radiation. This study highlights a translationally relevant nanotherapeutic approach for enhancing chemoradiotherapy outcomes in solid malignancies.

273

News (Medical) associated with Carfilzomib

11 Mar 2026

·allsci.com

BMS upbeat on protein degrader mezigdomide after Phase III results in relapsed multiple myeloma

Bristol Myers Squibb (BMS; NYSE: BMY) announced positive interim results from the SUCCESSOR-2 study, a Phase III trial evaluating oral mezigdomide in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. The readout marks the first positive Phase III study for mezigdomide and the second for the company’s CELMoD program, a platform of next-generation cereblon-modulating protein degraders central to BMS’s hematology pipeline. SUCCESSOR-2 (NCT05552976) is a seamless Phase II/III, multicenter, randomized, open-label trial comparing mezigdomide plus carfilzomib and dexamethasone (MeziKd) against carfilzomib and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma previously exposed to anti-CD38 therapy and lenalidomide. The primary endpoint of the Phase III portion was progression-free survival. According to the company, MeziKd demonstrated a statistically significant and clinically meaningful improvement in PFS over Kd. Exact hazard ratios, median PFS values, and p-values were not disclosed in the topline release. Safety findings were consistent with the known profile of mezigdomide and the combination regimen, with no new signals reported. Key secondary endpoints — including overall survival, overall response rate, duration of response, MRD negativity, and health-related quality of life — will be reported at a future medical meeting. Patients continue to be followed for survival and safety. BMS stated that data will be shared with health authorities, with no specific NDA filing timeline disclosed. Cristian Massacesi, the company’s chief medical officer, said the results “reinforce the value of our CELMoD program and our targeted protein degradation platform” and “strengthen our confidence in bringing forward effective, accessible oral treatment options”. Mezigdomide is a cereblon E3 ligase modulator (CELMoD) designed to bind cereblon, a substrate receptor of the CRL4 E3 ubiquitin ligase complex, and redirect the complex to ubiquitinate and degrade the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). These proteins play key roles in the growth and survival of malignant plasma cells in multiple myeloma. By promoting their degradation, CELMoD agents enhance anti-tumor immune activity and induce myeloma cell death. The mechanism builds on the established immunomodulatory drug (IMiD) class, which includes lenalidomide and pomalidomide, therapies that have become central components of current multiple myeloma treatment regimens. Multiple myeloma remains an incurable malignancy characterized by repeated cycles of response and relapse. While treatment options for relapsed or refractory multiple myeloma (RRMM) have expanded substantially in recent years — including bispecific antibodies, CAR-T cell therapies, and antibody-drug conjugates — patients who have progressed on anti-CD38 antibodies and lenalidomide often face limited therapeutic options. In this setting, orally administered agents that can be combined with existing backbone regimens remain an important area of clinical development. The competitive landscape in RRMM spans several therapeutic modalities. Key competing assets include: Bristol Myers Squibb’s iberdomide, another CELMoD agent currently being evaluated in Phase III trials in combination with daratumumab and dexamethasone in relapsed or refractory multiple myeloma. Johnson & Johnson’s talquetamab, a bispecific antibody targeting GPRC5D and CD3 that is being evaluated in Phase III trials for relapsed disease. Pfizer’s elranatamab, a BCMA×CD3 bispecific antibody that received US FDA approval for relapsed or refractory multiple myeloma and is undergoing further Phase III evaluation. Johnson & Johnson and Legend Biotech’s BCMA-directed CAR-T therapy ciltacabtagene autoleucel, which the US FDA approved for multiple myeloma and is being studied in additional Phase III trials across earlier treatment lines. GSK’s BCMA-targeted antibody-drug conjugate belantamab mafodotin, which is being evaluated in ongoing Phase III combination studies following earlier regulatory setbacks. Mezigdomide’s oral administration and compatibility with established backbone regimens such as carfilzomib plus dexamethasone could position it as a convenient treatment option in later-line settings. However, the therapy’s eventual role in the treatment sequence will depend on the magnitude and durability of clinical benefit observed in Phase III studies relative to existing immunotherapies and cell-based approaches. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Phase 3Clinical ResultImmunotherapyCell TherapyDrug Approval

10 Mar 2026

·www.biospace.com

TECVAYLI®▼ (teclistamab) monotherapy application submitted to the EMA for relapsed/refractory multiple myeloma after at least one prior therapy

Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy 1 Teclistamab monotherapy delivered superior progression-free survival and overall survival versus standard of care, reducing the risk of disease progression or death by 71% in a high unmet need patient population 2 BEERSE, BELGIUM, March 10, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking approval for an indication extension of TECVAYLI ® ▼(teclistamab) as monotherapy for the treatment of adult patients with relapsed/refractory multiple myeloma (RRMM) who have received at least one prior therapy. Bringing new hope to a high unmet need population Despite major advances in frontline multiple myeloma treatment, including anti-CD38-based quadruplet regimens, most patients will ultimately relapse. 2 Outcomes are particularly poor once patients become refractory to key backbone therapies such as anti‑CD38 monoclonal antibodies and lenalidomide. 2,3 This patient population has historically faced limited choices and challenging second-line treatment pathways, reinforcing the need for additional effective immunotherapy options that can be given across practice settings. 3 “A significant number of patients with multiple myeloma continue to relapse and become refractory to currently available therapies, representing one of the largest and most challenging unmet needs in the disease,” said Ester in ’t Groen, EMEA Therapeutic Area Head, Haematology, Johnson & Johnson. “Making teclistamab monotherapy available to patients as early as second line, where it has the potential to meaningfully improve long-term outcomes and change the course of the disease, could bring new hope to patients and their families.” MajesTEC-9 study results The submission is supported by data from the Phase 3 MajesTEC-9 trial evaluating the efficacy and safety of teclistamab versus the standard of care of pomalidomide, bortezomib, and dexamethasone (PVd) or carfilzomib and dexamethasone (Kd) in 614 patients with RRMM. 1 Results show teclistamab delivers superior progression-free survival (PFS) and overall survival (OS) versus standard of care as early as second line, including a 71% reduction in the risk of disease progression or death (hazard ratio [HR], 0.29; 95% confidence interval [CI], 0.23-0.38) and a 40% reduction in the risk of death (HR, 0.60; 95% CI, 0.43-0.83) in a patient population that was predominantly refractory to anti-CD38 monoclonal antibodies and lenalidomide. 2 The safety pro teclistamab monotherapy was clinically manageable and consistent with its known profile, with no new safety signals identified. 2 Infections can be managed with robust infection management protocols, which include patient monitoring, immunoglobulin therapy and antimicrobial prophylaxis. 4 The Independent Data Monitoring Committee recommended unblinding the study based on the strength of the data in the first pre-specified interim analysis. 2 This submission represents the first of several planned global regulatory filings, with full results to be presented at a future major medical meeting. “At Johnson & Johnson, we are driven by a clear purpose to deliver innovations that redefine expectations of what a multiple myeloma diagnosis means to patients, at every stage of the disease,” said Jordan Schecter, M.D., Vice President, Disease Area Leader, Multiple Myeloma, Johnson & Johnson. “With today’s regulatory milestone for teclistamab, we are advancing a widely available immunotherapy approach with the potential to support deep and sustained responses over time.” About the MajesTEC-9 study MajesTEC-9 (NCT05572515) is an ongoing, Phase 3 randomised study evaluating the safety and efficacy of teclistamab as a monotherapy versus pomalidomide, bortezomib and dexamethasone (PVd) or carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma (RRMM) who have received 1–3 prior lines of therapy, including an anti-CD38 monoclonal antibody and lenalidomide. 1 The majority of patients enrolled were refractory to anti-CD38 monoclonal antibodies (85%) and lenalidomide (79%) and more than 90% were refractory to their last line of therapy. 2 The primary endpoints are progression-free survival (PFS) and the number of participants reporting cytokine release syndrome (CRS) cases by severity. 1 Secondary endpoints include complete response or better (≥CR); duration of response (DOR); time to next treatment (TTNT); progression-free survival on next-line therapy (PFS2); overall survival (OS); number of participants with adverse events (AEs) and serious adverse events (SAEs) by severity; change from baseline in symptoms, functioning and overall health-related quality of life (HRQoL) as assessed by the European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30); and time to worsening in symptoms, functioning and overall HRQoL. 1 The MajesTEC-9 study is a part of the MajesTEC clinical programme, which includes exploring the potential of teclistamab as a combination regimen. 1 About Teclistamab Teclistamab received European Commission (EC) approval in August 2022 for the treatment of patients with RRMM who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. 5 In August 2023, the EC approved a Type II variation application for teclistamab, providing the option for a reduced dosing frequency of 1.5mg/kg every two weeks in patients who have achieved a complete response (CR) or better for a minimum of six months. 6 Teclistamab is an off-the-shelf (or ready-to-use) bispecific antibody. 4,7 Teclistamab, a subcutaneous injection, redirects T-cells through two cellular targets (BCMA and CD3) to activate the body’s immune system to fight cancer. Teclistamab is currently being evaluated in several combination studies. 4,8,9,10,11 For a full list of adverse events and information on dosage and administration, contraindications and other precautions when using teclistamab, please refer to the Summary of Product Characteristics at: . ▼ In line with EMA regulations for new medicines and those given conditional approval, teclistamab is subject to additional monitoring. 6 About Multiple Myeloma Multiple myeloma is currently an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow. 12 ,13 In multiple myeloma, these malignant plasma cells continue to proliferate, accumulating in the body and crowding out normal blood cells, as well as often causing bone destruction and other serious complications. 12,13 In the European Union, it is estimated that more than 35,000 people were diagnosed with multiple myeloma in 2022, and more than 22,700 patients died. 14 Patients living with multiple myeloma experience relapses which become more frequent with each line of therapy, while remissions become progressively shorter. 15 ,16,17 Whilst some patients with multiple myeloma initially have no symptoms, others can have common signs and symptoms of the disease, which can include bone fracture or pain, low red blood cell counts, fatigue, high calcium levels, infections, or kidney damage. 18 About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at . Follow us at . Cautions Concerning Forward-Looking Statements This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of teclistamab. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. END Key Search Terms MajesTEC-9 Phase 3 clinical trial TECVAYLI Teclistamab Teclistamab monotherapy Relapsed and or refractory multiple myeloma (RRMM) Early relapse multiple myeloma Second-line multiple myeloma treatment First relapse therapy for multiple myeloma Treatment resistance in multiple myeloma Progression-free survival (PFS) in multiple myeloma Overall survival (OS) in multiple myeloma Multiple myeloma Bispecific antibody therapy BCMA-targeted bispecific therapy EMEA haematology pipeline Multiple myeloma innovation Multiple myeloma treatment [1] ClinicalTrials.gov. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9). Available at: . Last accessed: March 2026. [2] Johnson & Johnson.com. TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide. Available at: . Last accessed: March 2026. [3] Ramasamy K, et. al. Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody. Clin Lymphoma Myeloma Leuk. 2025 May;25(5):337-348.e2. [4] European Medicines Agency. TECVAYLI Summary of Product Characteristics. Available at: . Last accessed: March 2026. [5] Johnson & Johnson.com. Janssen Marks First Approval Worldwide for TECVAYLI®▼(teclistamab) with EC Authorisation of First-in-Class Bispecific Antibody for the Treatment of Patients with Multiple Myeloma. Available at: . Last accessed: March 2026. [6] Johnson & Johnson.com. European Commission Approves Reduced Dosing Frequency for Janssen’s Bispecific Antibody TECVAYLI®▼ (teclistamab). Available at: . Last accessed: March 2026. [7] Moreau P, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine. 2022;287(6):494-505. [8] ClinicalTrials.gov. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3). Available at: . Last accessed: March 2026. [9] ClinicalTrials.gov. A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (MajesTEC-2). Available at: . Last accessed: March 2026. [10] ClinicalTrials.gov. A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma. Available at: . Last accessed: March 2026. [11] ClinicalTrials.gov. A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma. Available at: . Last accessed: March 2026. [12] Abdi J, et al. Drug Resistance in Multiple Myeloma: Latest Findings on Molecular Mechanisms. Oncotarget. 2013;4(12):2186-2207. [13] American Society of Clinical Oncology. Multiple Myeloma: Introduction. Available at: . Last accessed: March 2026. [14] ECIS - European Cancer Information System. Estimates of Cancer Incidence and Mortality in 2022, by Country. Multiple Myeloma. Available at: $0-0$1-All$2-All$4-1,2$3-51$6-0,85$5-2022,2022$7-7$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 . Last accessed: March 2026. [15] Bhatt P, et al. Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. Curr Oncol. 2023;30(2):2322-2347. [16] Hernández-Rivas JÁ, et al. The Changing Landscape of Relapsed and/or Refractory Multiple Myeloma (MM): Fundamentals and Controversies. Biomark Res. 2022;10(1):1-23. [17] Gavriatopoulou M, et al. Metabolic Disorders in Multiple Myeloma. Int J Mol Sci. 2021;22(21):11430. [18] American Cancer Society. Multiple Myeloma: Early Detection, Diagnosis and Staging. Available at: Last accessed: March 2026. CONTACT: Media contact: Jenni Mildon jmildon@its.jnj.com +44 7920 418 552 Investor contact: Jessica Margevich investor-relations@its.jnj.com

Phase 3Clinical ResultDrug ApprovalImmunotherapyASCO

09 Mar 2026

·www.fiercebiotech.com

BMS builds momentum for CELMoD drug after improving myeloma PFS in phase 3

BMS’ Chief Medical Officer, Cristian Massacesi, M.D., said this morning’s mezigdomide results “reinforce the value of our CELMoD program.”\n Bristol Myers Squibb’s mezigdomide has scored its first phase 3 win, with the Cereblon E3 ligase modulator (CELMoD) tied to a statistically significant improvement in progression-free survival (PFS) among multiple myeloma patients.The Successor-2 trial compared a combination of mezigdomide, Amgen’s cancer drug Kyprolis (carfilzomib), and the corticosteroid dexamethasone with carfilzomib and dexamethasone alone in patients with relapsed or refractory multiple myeloma. The oral mezigdomide regimen hit the study’s primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in PFS, the company said in a March 9 release. Safety findings were “consistent with the known profile of mezigdomide and the combination regimen,” said BMS, which is continuing the study so it can assess the key secondary endpoint of overall survival.The company is holding back detailed data for a future medical conference and said it will also share the findings with health authorities.The positive mezigdomide data comes six months after BMS’ CELMoD program scored another hit when a combination of iberdomide, the approved CD38 drug Darzalex and the steroid dexamethasone met one of the dual primary endpoints in a phase 3 multiple myeloma trial. BMS’ Chief Medical Officer, Cristian Massacesi, M.D., said this morning’s mezigdomide results “reinforce the value of our CELMoD program and our targeted protein degradation platform, and strengthen our confidence in bringing forward effective, accessible oral treatment options for patients with difficult-to-treat blood cancers and potentially beyond.”William Blair analysts said they continue to believe the CELMoD program “has potential to be a key long-term growth driver” for BMS. While this morning’s data are helping build momentum for mezigdomide, they suggested that the “most strategically important readout” for mezigdomide will be a head-to-head study against BMS’ myeloma drug Pomalyst, which is expected to deliver data next year.Meanwhile, BMS is evaluating iberdomide against its own Revlimid and is expecting to read out a phase 2 study of another CELMoD drug, golcadomide, later this year.

Phase 3Clinical ResultPhase 2Phase 1

100 Deals associated with Carfilzomib

External Link

KEGG	Wiki	ATC	Drug Bank
D08880	Carfilzomib	L01XX45	DB08889

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Multiple Myeloma	United States	Onyx Pharmaceuticals, Inc.	20 Jul 2012

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Refractory Multiple Myeloma	Phase 3	United States	Amgen, Inc.	08 May 2019
Refractory Multiple Myeloma	Phase 3	Japan	Amgen, Inc.	08 May 2019
Refractory Multiple Myeloma	Phase 3	Austria	Amgen, Inc.	08 May 2019
Refractory Multiple Myeloma	Phase 3	Bulgaria	Amgen, Inc.	08 May 2019
Refractory Multiple Myeloma	Phase 3	Czechia	Amgen, Inc.	08 May 2019
Refractory Multiple Myeloma	Phase 3	Finland	Amgen, Inc.	08 May 2019
Refractory Multiple Myeloma	Phase 3	France	Amgen, Inc.	08 May 2019
Refractory Multiple Myeloma	Phase 3	Germany	Amgen, Inc.	08 May 2019
Refractory Multiple Myeloma	Phase 3	Greece	Amgen, Inc.	08 May 2019
Refractory Multiple Myeloma	Phase 3	Lithuania	Amgen, Inc.	08 May 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05896228 (ReKInDLE, ASH2025)	Phase 2	Relapse multiple myeloma	30	Iberdomide+Carfilzomib+Daratumumab+Dexamethasone	uyjttuvzdj(liijdmpenc) = Grade 3 or greater events included neutropenia (50%), lymphocytopenia (40%), leukopenia (23%), thrombocytopenia (10%), and anemia (3%) but were manageable with growth factor support and/or iber dose-reduction, as needed. hvqktoxlyx (khszkmzjjc ) View more	Positive	06 Dec 2025
NCT03729804 (COBRA, ASH2025)	Phase 3	Multiple Myeloma	250	Carfilzomib, lenalidomide, and dexamethasone (KRd)	riyphslxai(jrqdgjfafd) = xhiotwkubz vfzfpltnlf (bberkpdqrs ) View more	Positive	06 Dec 2025
				Bortezomib, lenalidomide, and dexamethasone (VRd)	riyphslxai(jrqdgjfafd) = tnoeakfrev vfzfpltnlf (bberkpdqrs ) View more
NCT04268498 (ADVANCE, ASH2025)	Phase 2	Multiple Myeloma	306	DKRd	urjehbrhsx(ydmpycuepg) = scuokwdbzv mvwykleglw (ramyixntej ) View more	Positive	06 Dec 2025
				KRd	urjehbrhsx(ydmpycuepg) = vqkhapavji mvwykleglw (ramyixntej ) View more
ASH2025	Not Applicable	Multiple Myeloma	35	Carfilzomib + high-dose melphalan	chjzbuyckd(nsxotutzne) = 91.4% dxmvfynlot (zfqgnuwjxn ) View more	Positive	06 Dec 2025
NCT05789303 (ASH2025)	Phase 2	Multiple Myeloma	11	Belantamab mafodotin+Carfilzomib+Pomalidomide+Dexamethasone	tmmyddadly(bgywrdnrrg) = pdybrzyque lsesqfnvxx (qorvqalkjq ) View more	Positive	06 Dec 2025
NCT06409702 (ASH2025)	Phase 1	Multiple Myeloma	58	Daratumumab+Carfilzomib+Lenalidomide+Dexamethasone (DKRd)	rhqmuoycuz(wfjffdfhoj) = yavoiyrhjq njekecqzgx (suqlolaorg ) View more	Positive	06 Dec 2025
NCT02937571 (CTgov)	Phase 1/2	Multiple Myeloma \| Plasma Cell Leukemia \| Bone Marrow Neoplasms	29	Carfilzomib (Dose Level 1: Carfilzomib 45mg/m2/Dose)	wzsfpntckm = zhgjfwgftw zniavlrzfi (ebtvgvncyk, yiwnaukrhs - feqhkqjydh) View more	-	20 Nov 2025
				Carfilzomib (Dose Level 2: Carfilzomib 56mg/m2/Dose)	wzsfpntckm = bkrupgxbaq zniavlrzfi (ebtvgvncyk, ehrghvysjx - junyqnfxhu) View more
NCT02969837 (CTgov)	Phase 2	Multiple Myeloma	46	Lenalidomide+Elotuzumab+Carfilzomib+Dexamethasone	auchcyfsza = unlkvemeaw ztndmsrvxh (tiluzggtom, wcousuepig - coctvhqfsv) View more	-	10 Sep 2025
NCT05556616 (iinnovate-2, CTgov)	Phase 1	Multiple Myeloma	15	Lenalidomide+Modakafusp alfa (Group 1 (NDMM): Modakafusp Alfa 80 mg + Lenalidomide 10 mg)	lexltfsrqz = zaztstcntw etjuvdinha (qghqkkptbj, jpkkmnzpeg - lcpmfmeoyi) View more	-	06 Aug 2025
				Modakafusp alfa+Pomalidomide (Group 2 (RRMM Doublets): Modakafusp Alfa 80 mg + Pomalidomide 2 mg)	lexltfsrqz = nzisaujdsg etjuvdinha (qghqkkptbj, uuqcrpaawh - ylbbydwtgq) View more
ASCO2025	Not Applicable	Refractory Multiple Myeloma	-	Carfilzomib	liyplmyolw(obkxvuwylv): aOR = 1.61 (95% CI, 1.48 - 1.77), P-Value = < 0.001 View more	Negative	30 May 2025
				No Carfilzomib

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis